Search Results
Sep 03, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR
information about joining the class action]In late 2024, Capricor submitted its Biologics License Application ("BLA") to the U.S. Food and Drug Administration for Deramiocel as a cell therapy for the treatment of Duchenne muscular dystrophy. In July 2025, the FDA issued a Complete Response
More news about: Pomerantz LLP
Sep 03, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
2, 2026.Then, on May 14, 2026, Aardvark issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company's previously announced voluntary pause." The press release
More news about: Pomerantz LLP
Sep 03, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Wise Group plc of Class Action Lawsuit and Upcoming Deadlines - WSE
nearing completion, concerns potential money laundering offences, with alleged links to fraud, corruption and drug trafficking" and that "[p]rosecutors are investigating whether Wise Europe's services were used by international criminal organisations,
More news about: Pomerantz LLP
Sep 03, 2026, 10:00 ET TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
TraceLink, the world's largest Agentic Business Network for the life sciences and healthcare supply chain, today announced an integration between its Drug Supply Chain Security Act (DSCSA) compliance solution and the pharmacy inventory management systems of Omnicell, Inc. (Nasdaq: OMCL), a leading healthcare
More news about: TraceLink, Inc.
Sep 03, 2026, 10:00 ET TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
TraceLink, the world's largest Agentic Business Network for the life sciences and healthcare supply chain, today announced an integration between its Drug Supply Chain Security Act (DSCSA) compliance solution and the pharmacy inventory management systems of Omnicell, Inc. (Nasdaq: OMCL), a leading healthcare
More news about: TraceLink, Inc.
Sep 03, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers - GUTS
Fractyl's "REMAIN-1" study, evaluating Revita's efficacy in maintaining weight loss following the discontinuation of GLP-1 receptor agonist drug therapy. The REMAIN-1 study is designed to include three distinct patient cohorts: (i) the REVEAL-1 Cohort; (ii) the REMAIN-1 Midpoint Cohort; and
More news about: Pomerantz LLP
Sep 03, 2026, 09:41 ET Mammotome Accelerates Production as Public Health Response to Nationwide Breast Biopsy Needle Shortage
Earlier this year, the U.S. Food and Drug Administration (FDA) notified providers of interruptions in the supply of stereotactic breast biopsy needles and added them to its Medical Device Shortages
More news about: Mammotome
Sep 03, 2026, 09:15 ET AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed (proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody) relapsed/refractory multiple myeloma (RRMM). The study met its dual primary endpoints of objective response
More news about: AbbVie
Sep 03, 2026, 09:05 ET HYDRINITY Accelerated Skin Science Expands into Panama Through Partnership with Comercializadora Guru SA
technologies including Supercharged HA™, MicroFusion™, and RetaXome™. Founded as a regenerative medicine company developing advanced wound care and drug delivery systems for oncology and hematology patients, HYDRINITY has since redefined dermatological skincare with clinically backed formulations featuring
More news about: HYDRINITY Accelerated Skin Science
Sep 03, 2026, 09:00 ET Ziploc® Brand and Too Good To Go Launch "Surprise Seconds" to Give Good Food a Second Act
food and home storage solution families trust. The Ziploc® brand offers more than 20 products, available in grocery, mass merchandise and drug stores nationwide, including: Ziploc® Freezer & Storage bags with Easy Open Tabs and Stay Open Design, Slider bags, Sandwich & Snack
More news about: Ziploc
Sep 03, 2026, 08:55 ET AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug discovery market at approximately $1.71 billion in 2024 and projects it will reach roughly $8.52 billion by 2030, a compound annual growth rate of about
More news about: Equity Insider
Sep 03, 2026, 08:50 ET Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program
autologous neural tissue transplant for the treatment of spinal cord injury, today announced that it has received written feedback from the U.S. Food and Drug Administration, FDA, Center for Biologics Evaluation and Research, CBER, regarding the proposed design of the Company's first in human clinical trial
More news about: Matricelf Ltd.
Sep 03, 2026, 08:38 ET Authenticx Expands Pharmacovigilance AI to Automate Downstream Safety Workflows With Accuracy
inconsistency to regulated workflows. Federal regulations require applicants to promptly review adverse drug experience information received from any source, with serious and unexpected adverse drug experiences generally reportable within 15 calendar days of receipt. Authenticx introduced its safety-event
More news about: Authenticx
Sep 03, 2026, 08:36 ET PharmPix President and CEO Dr. Martty Martínez Fraticelli Wins PBMI Excellence Award for Clinical Innovation
programs directly into the adjudication process rather than relying solely on retrospective analysis. Potential drug-related problems, including duplicate therapies, inappropriate dosing and drug interactions, can be identified at the point of sale and elevated for clinical review before a medication is
More news about: PharmPix
Sep 03, 2026, 08:30 ET Reduce ADC Conjugation Risk with Consistent Antibody Quality, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how consistent antibody quality can support efficient antibody-drug conjugate (ADC) manufacturing. The featured speaker will discuss antigen binding, structural stability, conjugation readiness and the role of upstream and downstream processes in maintaining antibody quality.
More news about: Xtalks
Sep 03, 2026, 08:30 ET Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).This release is intended for investors only. For additional information about Talphera, please visit
More news about: Talphera, Inc.
Sep 03, 2026, 08:30 ET Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would
More news about: Citius Pharmaceuticals, Inc.
Sep 03, 2026, 08:15 ET Legacy Healthcare Welcomes U.S. Congressional Legislation Proposing 12-Year Market Exclusivity for US FDA Newly Approved Botanical Drugs
to attract investment in this emerging drug category – much favored by patients."Legacy Healthcare's lead candidate – Cinainu – is the first botanical drug for an autoimmune disease authorized to enter Phase 3 by the U.S. Food and Drug Administration and Japanese health authorities
More news about: Legacy Healthcare
Sep 03, 2026, 08:01 ET FIRST IN THE BALTICS: NORTHWAY BIOTECH OPENS €61 MILLION CELL THERAPY AND PERSONALIZED MEDICINE CDMO IN VILNIUS
destroy specific cancer cells. In parallel, 3D human tissue technologies are being developed to create more physiologically relevant tissue models, study drug effects, and advance regenerative medicine solutions.Northway's expertise in cell biology and tissue engineering will also be further applied
More news about: Northway Biotech
Sep 03, 2026, 08:00 ET Triquetra Health Launches Saffron Kids™--First USDA Organic Sargol-Grade Saffron Extract Studied in Children at the Label Dose
[email protected]+ (844) 272-6337These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
More news about: Triquetra Health LLC
Sep 03, 2026, 07:15 ET ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
days.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC
More news about: ADC Therapeutics SA
Sep 03, 2026, 07:00 ET Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). Current international treatment guidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily
More news about: Insmed Incorporated
Sep 03, 2026, 07:00 ET Gravie Launches Industry's First Hybrid Benefit Solution as an Answer to Employers Facing Rising Healthcare Costs
small and midsize businesses heading into 2027, as these companies continue to face particular pressure from rising hospital, physician and prescription drug costs. At the same time, employers and benefits brokers are increasingly considering alternatives to traditional fully insured coverage, including both
More news about: Gravie, Inc
Sep 03, 2026, 07:00 ET Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing to support full commercialization.Forward
More news about: Armata Pharmaceuticals, Inc.
Sep 03, 2026, 06:40 ET Potassium Fluoride Market worth $0.51 billion by 2032 - Exclusive Report by MarketsandMarkets™
potassium fluoride market has diversified its demand to several applications, including use in chemicals manufacturing, agriculture, pharmaceutical drug manufacturing, glass etching, metal treating, flux used for soldering, and semiconductor production. Potassium Fluoride is an important source of fluoride
More news about: MarketsandMarkets